Fibrobiologics Inc (FBLG)

$0.28 -0.01 (-2.26%)
Market Cap 22.07M
Revenue (ttm) 0.00
Net Income (ttm) -11.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 35.15
Volume 522,100
Avg Vol 2,161,072
Day's Range N/A - N/A
Shares Out 66.52M
Stochastic %K 10%
Beta -0.54
Analysts Strong Sell
Price Target $7.00

Company Profile

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 281 651 5150
Address:
455 East Medical Center Boulevard, Suite 300, Houston, United States
MisoHawny
MisoHawny Feb. 3 at 10:41 PM
$FBLG 22 is possible
0 · Reply
Enoch120
Enoch120 Feb. 3 at 1:14 PM
$FBLG https://www.nasdaq.com/market-activity/stocks/fblg/institutional-holdings As 12/31/25 holdings start trickling in from institutions it is obvious that sells outpace buys for the quarter. When the stutes start buying again this stock should rocket. News of successful trials should be the catalyst. We'll see.
0 · Reply
MisoHawny
MisoHawny Feb. 2 at 4:55 PM
$FBLG ooooopppppsssiiiiieeeeeee…..
0 · Reply
dkstew
dkstew Feb. 2 at 4:05 PM
$FBLG down 5c ... does somebody know the IND was rejected, or is this the proverbial 'bear raid' before news?
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 3:23 PM
$FBLG RSI: 35.57, MACD: 0.0129 Vol: 0.04, MA20: 0.34, MA50: 0.30 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Wnt531
Wnt531 Jan. 29 at 12:22 AM
$FBLG a microcap biotech has real science and upcoming catalysts, it stops being a lottery ticket and starts being a setup. $FBLG is getting interesting fast. Eyes open
2 · Reply
BigD_Love
BigD_Love Jan. 28 at 1:40 PM
$FBLG Decision of IND given to the FDA expected any day now…👊🏻
0 · Reply
KardiTheViking
KardiTheViking Jan. 26 at 1:01 PM
$FBLG cmon :)
0 · Reply
peepthestamp
peepthestamp Jan. 23 at 9:11 PM
$FBLG
0 · Reply
Cookem_up09
Cookem_up09 Jan. 23 at 9:11 PM
$FBLG Curious to see how the price will respond after the dealflow conference
1 · Reply
Latest News on FBLG
FibroBiologics to Present at the DealFlow Discovery Conference

Jan 20, 2026, 8:30 AM EST - 14 days ago

FibroBiologics to Present at the DealFlow Discovery Conference

FibroBiologics CEO Issues Letter to Shareholders

Jan 7, 2026, 8:30 AM EST - 27 days ago

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

Jan 6, 2026, 8:30 AM EST - 4 weeks ago

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

Jan 5, 2026, 8:30 AM EST - 4 weeks ago

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

Dec 31, 2025, 8:30 AM EST - 4 weeks ago

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:05 PM EST - 7 weeks ago

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 7 weeks ago

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Files New Patent For Fibroblast Tech To Advance Deeper Into Orthopedics

Dec 10, 2025, 11:36 AM EST - 7 weeks ago

FibroBiologics Files New Patent For Fibroblast Tech To Advance Deeper Into Orthopedics

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Dec 10, 2025, 8:30 AM EST - 7 weeks ago

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

FibroBiologics Announces Payoff of Outstanding Debt

Nov 26, 2025, 8:30 AM EST - 2 months ago

FibroBiologics Announces Payoff of Outstanding Debt

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 4:05 PM EST - 2 months ago

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 24, 2025, 9:00 AM EST - 2 months ago

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Nov 20, 2025, 8:00 AM EST - 2 months ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 7:03 PM EST - 2 months ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 8:36 AM EST - 2 months ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 4:30 PM EDT - 3 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics to Present at Bio-Europe 2025

Oct 24, 2025, 8:30 AM EDT - 3 months ago

FibroBiologics to Present at Bio-Europe 2025

FibroBiologics to Present at the 2025 ThinkEquity Conference

Oct 14, 2025, 8:30 AM EDT - 4 months ago

FibroBiologics to Present at the 2025 ThinkEquity Conference

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

Sep 23, 2025, 8:30 AM EDT - 4 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

Sep 12, 2025, 8:30 AM EDT - 5 months ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Sep 11, 2025, 8:30 AM EDT - 5 months ago

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

Sep 10, 2025, 8:30 AM EDT - 5 months ago

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:30 AM EDT - 5 months ago

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 31, 2025, 4:30 PM EDT - 6 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Jul 28, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

FibroBiologics to Present at the Advanced Wound Care Summit USA

Jul 11, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

Jul 9, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

Jul 7, 2025, 4:35 PM EDT - 7 months ago

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

Jun 16, 2025, 4:35 PM EDT - 8 months ago

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

FibroBiologics to Present at the BIO International Convention 2025

Jun 16, 2025, 9:50 AM EDT - 8 months ago

FibroBiologics to Present at the BIO International Convention 2025

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

Jun 9, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

May 16, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:30 PM EDT - 9 months ago

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Presenting at the ThymUS 2025 Meeting

Apr 29, 2025, 9:15 AM EDT - 10 months ago

FibroBiologics Presenting at the ThymUS 2025 Meeting

FibroBiologics Presents at the ThymUS 2025 Meeting

Apr 29, 2025, 9:15 AM EDT - 10 months ago

FibroBiologics Presents at the ThymUS 2025 Meeting

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

Apr 11, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

Apr 8, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

Apr 2, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:25 PM EDT - 11 months ago

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

FibroBiologics Announces 2025 Annual Meeting of Stockholders

Mar 27, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics Announces 2025 Annual Meeting of Stockholders

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

Mar 21, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

Mar 4, 2025, 8:30 AM EST - 1 year ago

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

Feb 27, 2025, 8:30 AM EST - 1 year ago

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

Feb 5, 2025, 9:15 AM EST - 1 year ago

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing

Dec 30, 2024, 4:30 PM EST - 1 year ago

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

Dec 30, 2024, 2:12 PM EST - 1 year ago

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

FibroBiologics Announces $25 Million Financing

Dec 23, 2024, 7:55 AM EST - 1 year ago

FibroBiologics Announces $25 Million Financing

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

Nov 19, 2024, 9:15 AM EST - 1 year ago

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

Nov 14, 2024, 9:15 AM EST - 1 year ago

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:20 PM EST - 1 year ago

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

MisoHawny
MisoHawny Feb. 3 at 10:41 PM
$FBLG 22 is possible
0 · Reply
Enoch120
Enoch120 Feb. 3 at 1:14 PM
$FBLG https://www.nasdaq.com/market-activity/stocks/fblg/institutional-holdings As 12/31/25 holdings start trickling in from institutions it is obvious that sells outpace buys for the quarter. When the stutes start buying again this stock should rocket. News of successful trials should be the catalyst. We'll see.
0 · Reply
MisoHawny
MisoHawny Feb. 2 at 4:55 PM
$FBLG ooooopppppsssiiiiieeeeeee…..
0 · Reply
dkstew
dkstew Feb. 2 at 4:05 PM
$FBLG down 5c ... does somebody know the IND was rejected, or is this the proverbial 'bear raid' before news?
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 3:23 PM
$FBLG RSI: 35.57, MACD: 0.0129 Vol: 0.04, MA20: 0.34, MA50: 0.30 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Wnt531
Wnt531 Jan. 29 at 12:22 AM
$FBLG a microcap biotech has real science and upcoming catalysts, it stops being a lottery ticket and starts being a setup. $FBLG is getting interesting fast. Eyes open
2 · Reply
BigD_Love
BigD_Love Jan. 28 at 1:40 PM
$FBLG Decision of IND given to the FDA expected any day now…👊🏻
0 · Reply
KardiTheViking
KardiTheViking Jan. 26 at 1:01 PM
$FBLG cmon :)
0 · Reply
peepthestamp
peepthestamp Jan. 23 at 9:11 PM
$FBLG
0 · Reply
Cookem_up09
Cookem_up09 Jan. 23 at 9:11 PM
$FBLG Curious to see how the price will respond after the dealflow conference
1 · Reply
Malachi_4
Malachi_4 Jan. 23 at 8:57 PM
$FBLG How could a potential R/S impact the stock price
1 · Reply
Ainvestigator
Ainvestigator Jan. 23 at 1:04 AM
$FBLG took a positionon on that 25¢ dip Last month! Sleeper?!🚨🚨🚨🤫🤫🤫 ✅✅✅🔥🔥🔥 Lets goo!
0 · Reply
MisoHawny
MisoHawny Jan. 21 at 1:15 PM
$FBLG will likely explore to 26 before a much more meaningful rise. 
0 · Reply
Peace2026
Peace2026 Jan. 20 at 3:08 PM
$FBLG https://sg.finance.yahoo.com/news/fibrobiologics-present-dealflow-discovery-conference-133000281.html
0 · Reply
MisoHawny
MisoHawny Jan. 15 at 1:03 PM
$FBLG 28 - 31 on deck
0 · Reply
hanna938
hanna938 Jan. 14 at 3:43 AM
$FBLG This is moving in overnight!! GLTA
0 · Reply
MisoHawny
MisoHawny Jan. 13 at 6:05 PM
$FBLG oooooppppssiieeeee…. Let’s hope we actually bounce back. 
0 · Reply
MisoHawny
MisoHawny Jan. 13 at 3:21 PM
$FBLG we’re not done yet, but we might retrace to 33 first.
0 · Reply
XING851653619
XING851653619 Jan. 13 at 3:03 PM
$FBLG I told you about the changes that were going to happen at the company a week ago. The stock price was around 25 cents then.
1 · Reply
XING851653619
XING851653619 Jan. 13 at 3:01 PM
$FBLG Do you believe me now?
0 · Reply
hanna938
hanna938 Jan. 13 at 2:16 PM
$FBLG
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 9:31 PM
After Hours Top Gainers PT2 $DRCT $BGMS $FBLG $LVLU $QTRX
0 · Reply